Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?

Marissa L.G. Vane* (Corresponding Author), Maria A. Willemsen, Lori M. van Roozendaal, Sander M.J. van Kuijk, Loes F.S. Kooreman, Sabine Siesling, Hans H.W. de Wilt, Marjolein L. Smidt

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

Objective: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). Summary background data: ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1–2 positive SLN(s). Methods: All cT1-2N0 breast cancer patients with 1–3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Logistic regression analysis was used to determine the association between ECE and ≥ 4 lymph node metastases. Five-year DFS and 10-year OS were analyzed using Kaplan–Meier survival analysis. Cox regression analysis was performed to correct for other prognostic factors. Results: A total of 3502 patients were included. Information on ECE was available for 2111 (60.3%) patients, consisting of 741 (35.1%) patients with and 1370 (64.9%) without ECE. The incidence of ≥ 4 lymph node metastases was 116 (15.7%) in the ECE group vs. 80 (5.8%) in the group without ECE (p < 0.001). Five-year DFS rate was 86.4% in the ECE group compared to 88.8% in the group without ECE (p = 0.085). 10-year OS rate was 78.6% compared to 83.0% (p = 0.018), respectively. Cox regression analysis showed that ECE was not an independent prognostic factor for both DFS and OS. Conclusions: ECE was significantly associated with involvement of ≥ 4 lymph node metastases in the completion ALND group. ECE was not an independent prognostic factor for both DFS and OS.

Original languageEnglish
Pages (from-to)711-718
Number of pages8
JournalBreast cancer research and treatment
Volume174
Issue number3
Early online date4 Jan 2019
DOIs
Publication statusPublished - 30 Apr 2019

Fingerprint

Disease-Free Survival
Lymph Node Excision
Breast Neoplasms
Lymph Nodes
Neoplasm Metastasis
Survival
Regression Analysis
Survival Rate
Survival Analysis
Netherlands
Registries
Breast
Logistic Models
Sentinel Lymph Node
Incidence
Neoplasms
Therapeutics

Keywords

  • UT-Hybrid-D
  • Breast cancer
  • Disease-free survival
  • Extracapsular extension
  • Overall survival
  • Sentinel lymph node
  • Axillary lymph node dissection

Cite this

Vane, M. L. G., Willemsen, M. A., van Roozendaal, L. M., van Kuijk, S. M. J., Kooreman, L. F. S., Siesling, S., ... Smidt, M. L. (2019). Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients? Breast cancer research and treatment, 174(3), 711-718. https://doi.org/10.1007/s10549-018-05074-y
Vane, Marissa L.G. ; Willemsen, Maria A. ; van Roozendaal, Lori M. ; van Kuijk, Sander M.J. ; Kooreman, Loes F.S. ; Siesling, Sabine ; de Wilt, Hans H.W. ; Smidt, Marjolein L. / Extracapsular extension in the positive sentinel lymph node : a marker of poor prognosis in cT1-2N0 breast cancer patients?. In: Breast cancer research and treatment. 2019 ; Vol. 174, No. 3. pp. 711-718.
@article{85481246736f42dca04489e2eeb18638,
title = "Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?",
abstract = "Objective: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). Summary background data: ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1–2 positive SLN(s). Methods: All cT1-2N0 breast cancer patients with 1–3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Logistic regression analysis was used to determine the association between ECE and ≥ 4 lymph node metastases. Five-year DFS and 10-year OS were analyzed using Kaplan–Meier survival analysis. Cox regression analysis was performed to correct for other prognostic factors. Results: A total of 3502 patients were included. Information on ECE was available for 2111 (60.3{\%}) patients, consisting of 741 (35.1{\%}) patients with and 1370 (64.9{\%}) without ECE. The incidence of ≥ 4 lymph node metastases was 116 (15.7{\%}) in the ECE group vs. 80 (5.8{\%}) in the group without ECE (p < 0.001). Five-year DFS rate was 86.4{\%} in the ECE group compared to 88.8{\%} in the group without ECE (p = 0.085). 10-year OS rate was 78.6{\%} compared to 83.0{\%} (p = 0.018), respectively. Cox regression analysis showed that ECE was not an independent prognostic factor for both DFS and OS. Conclusions: ECE was significantly associated with involvement of ≥ 4 lymph node metastases in the completion ALND group. ECE was not an independent prognostic factor for both DFS and OS.",
keywords = "UT-Hybrid-D, Breast cancer, Disease-free survival, Extracapsular extension, Overall survival, Sentinel lymph node, Axillary lymph node dissection",
author = "Vane, {Marissa L.G.} and Willemsen, {Maria A.} and {van Roozendaal}, {Lori M.} and {van Kuijk}, {Sander M.J.} and Kooreman, {Loes F.S.} and Sabine Siesling and {de Wilt}, {Hans H.W.} and Smidt, {Marjolein L.}",
note = "Springer deal",
year = "2019",
month = "4",
day = "30",
doi = "10.1007/s10549-018-05074-y",
language = "English",
volume = "174",
pages = "711--718",
journal = "Breast cancer research and treatment",
issn = "0167-6806",
publisher = "Springer",
number = "3",

}

Vane, MLG, Willemsen, MA, van Roozendaal, LM, van Kuijk, SMJ, Kooreman, LFS, Siesling, S, de Wilt, HHW & Smidt, ML 2019, 'Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?', Breast cancer research and treatment, vol. 174, no. 3, pp. 711-718. https://doi.org/10.1007/s10549-018-05074-y

Extracapsular extension in the positive sentinel lymph node : a marker of poor prognosis in cT1-2N0 breast cancer patients? / Vane, Marissa L.G. (Corresponding Author); Willemsen, Maria A.; van Roozendaal, Lori M.; van Kuijk, Sander M.J.; Kooreman, Loes F.S.; Siesling, Sabine; de Wilt, Hans H.W.; Smidt, Marjolein L.

In: Breast cancer research and treatment, Vol. 174, No. 3, 30.04.2019, p. 711-718.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Extracapsular extension in the positive sentinel lymph node

T2 - a marker of poor prognosis in cT1-2N0 breast cancer patients?

AU - Vane, Marissa L.G.

AU - Willemsen, Maria A.

AU - van Roozendaal, Lori M.

AU - van Kuijk, Sander M.J.

AU - Kooreman, Loes F.S.

AU - Siesling, Sabine

AU - de Wilt, Hans H.W.

AU - Smidt, Marjolein L.

N1 - Springer deal

PY - 2019/4/30

Y1 - 2019/4/30

N2 - Objective: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). Summary background data: ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1–2 positive SLN(s). Methods: All cT1-2N0 breast cancer patients with 1–3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Logistic regression analysis was used to determine the association between ECE and ≥ 4 lymph node metastases. Five-year DFS and 10-year OS were analyzed using Kaplan–Meier survival analysis. Cox regression analysis was performed to correct for other prognostic factors. Results: A total of 3502 patients were included. Information on ECE was available for 2111 (60.3%) patients, consisting of 741 (35.1%) patients with and 1370 (64.9%) without ECE. The incidence of ≥ 4 lymph node metastases was 116 (15.7%) in the ECE group vs. 80 (5.8%) in the group without ECE (p < 0.001). Five-year DFS rate was 86.4% in the ECE group compared to 88.8% in the group without ECE (p = 0.085). 10-year OS rate was 78.6% compared to 83.0% (p = 0.018), respectively. Cox regression analysis showed that ECE was not an independent prognostic factor for both DFS and OS. Conclusions: ECE was significantly associated with involvement of ≥ 4 lymph node metastases in the completion ALND group. ECE was not an independent prognostic factor for both DFS and OS.

AB - Objective: This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS). Summary background data: ECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1–2 positive SLN(s). Methods: All cT1-2N0 breast cancer patients with 1–3 positive SLN(s) who underwent ALND between 2005 and 2008 were selected from the Netherlands Cancer Registry. Logistic regression analysis was used to determine the association between ECE and ≥ 4 lymph node metastases. Five-year DFS and 10-year OS were analyzed using Kaplan–Meier survival analysis. Cox regression analysis was performed to correct for other prognostic factors. Results: A total of 3502 patients were included. Information on ECE was available for 2111 (60.3%) patients, consisting of 741 (35.1%) patients with and 1370 (64.9%) without ECE. The incidence of ≥ 4 lymph node metastases was 116 (15.7%) in the ECE group vs. 80 (5.8%) in the group without ECE (p < 0.001). Five-year DFS rate was 86.4% in the ECE group compared to 88.8% in the group without ECE (p = 0.085). 10-year OS rate was 78.6% compared to 83.0% (p = 0.018), respectively. Cox regression analysis showed that ECE was not an independent prognostic factor for both DFS and OS. Conclusions: ECE was significantly associated with involvement of ≥ 4 lymph node metastases in the completion ALND group. ECE was not an independent prognostic factor for both DFS and OS.

KW - UT-Hybrid-D

KW - Breast cancer

KW - Disease-free survival

KW - Extracapsular extension

KW - Overall survival

KW - Sentinel lymph node

KW - Axillary lymph node dissection

UR - http://www.scopus.com/inward/record.url?scp=85059522365&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-05074-y

DO - 10.1007/s10549-018-05074-y

M3 - Article

AN - SCOPUS:85059522365

VL - 174

SP - 711

EP - 718

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

SN - 0167-6806

IS - 3

ER -